Patents by Inventor Sharat Singh

Sharat Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INDIRECT HOMOGENEOUS MOBILITY SHIFT ASSAYS FOR THE DETECTION OF BIOLOGICS IN PATIENT SAMPLES
    Publication number: 20170328923
    Abstract: The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble ?4?7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.
    Type: Application
    Filed: May 23, 2017
    Publication date: November 16, 2017
    Applicant: Nestec S.A.
    Inventors: Jared Salbato, Stefan Westin, Nicholas Chi-Kwan Ling, Anjali Jain, Sharat Singh
  • METHODS FOR PREDICTION OF ANTI-TNF ALPHA DRUG LEVELS AND AUTOANTIBODY FORMATION
    Publication number: 20170315117
    Abstract: In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNF? drug during the course of anti-TNF? drug therapy. In other aspects, the present invention provides methods for predicting the level of an anti-TNF? drug in a subject during the course of anti-TNF? drug therapy. Systems for predicting anti-TNF? drug levels and the likelihood of autoantibody formation during the course of anti-TNF? drug therapy are also provided herein. The present invention further provides methods for predicting a clinical outcome (e.g., endoscopic response) of a subject on anti-TNF? drug therapy.
    Type: Application
    Filed: April 12, 2017
    Publication date: November 2, 2017
    Applicant: Nestec S.A.
    Inventors: Sharat Singh, Venkateswarlu Kondragunta
  • PATHWAY SPECIFIC MARKERS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME
    Publication number: 20170307637
    Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.
    Type: Application
    Filed: July 11, 2017
    Publication date: October 26, 2017
    Applicant: Nestec S.A.
    Inventors: Stefan Westin, Fabiyola Selvaraj, Fred Princen, Sharat Singh
  • ULTRA BRIGHT DIMERIC OR POLYMERIC DYES WITH SPACING LINKER GROUPS
    Publication number: 20170292957
    Abstract: Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Inventors: Tracy Matray, Sharat Singh
  • Methods for determining anti-drug antibody isotypes
    Patent number: 9784748
    Abstract: The present invention provides assay methods for the determination of one or more anti-drug antibody (ADA) isotypes in a sample. As a non-limiting example, the assays of the present invention are particularly useful for determining different ADA isotypes in samples from ADA-positive patients receiving an anti-TNF? drug such as REMICADE™ (infliximab) or HUMIRA™ (adalimumab). The present invention also provides methods for optimizing therapy and/or reducing toxicity in subjects receiving TNF? inhibitors for the treatment of TNF?-mediated disease or disorders.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: October 10, 2017
    Assignee: NESTEC S.A.
    Inventors: Shui Long Wang, Linda Ohrmund, Scott Hauenstein, Sharat Singh
  • METHODS FOR PREDICTING AND IMPROVING THE SURVIVAL OF GASTRIC CANCER PATIENTS
    Publication number: 20170285044
    Abstract: The present invention provides assays and methods for predicting the post-operative survival of a subject having an early stage gastric cancer after tumor surgery. The present invention also provides methods for treating a subject having an early stage gastric cancer by administering a combination therapy tailored to the signal transduction biomarkers that are activated in the cancer. In particular embodiments, the methods of the invention rely on the detection of the activation state or level of a specific combination of signal transducer analytes in a cancer cell obtained from the subject. Thus, the methods of the invention are particularly useful for predicting the survival or prognosis of a subject having an early stage gastric cancer and for guiding both pre- and post-operative treatment decisions by identifying subjects who would benefit from combination therapy as opposed to monotherapy.
    Type: Application
    Filed: June 14, 2017
    Publication date: October 5, 2017
    Applicant: Pierian Holdings, Inc.
    Inventors: Phillip Kim, Sharat Singh
  • METHODS FOR ESTABLISHING A VEDOLIZUMAB DOSING REGIMEN TO TREAT PATIENTS WITH IRRITABLE BOWEL DISEASE
    Publication number: 20170254806
    Abstract: The present invention provides methods for predicting whether an individual having inflammatory bowel disease (IBD) is likely to respond to vedolizumab treatment. Also provided are methods for predicting whether an individual with IBD such as Crohn's disease or ulcerative colitis will develop autoantibodies against vedolizumab. The present invention also provides a treatment regimen for an IBD patient which includes measuring the level of one or more predictive markers of response to vedolizumab prior to administering the anti-?4?7 integrin drug.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 7, 2017
    Applicant: Nestec S.A.
    Inventors: Sharat Singh, Anjali Jain, Venkateswarlu Kondragunta
  • ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF
    Publication number: 20170240652
    Abstract: The present invention provides antibodies and methods for preparing antibodies to metabolites in the serotonin, tryptophan and kynurenine pathways, such as 5-hydroxyindole-3-acetic acid (5-HIAA), melatonin (MT) and kynurenic acid (KYNA). The specific metabolite antibodies have low cross-reactivity to structurally related metabolites, and are useful reagents for specific and sensitive immunoassays. The present invention also provides methods for using such antibodies to measure the levels of 5-HIAA, melatonin, or kynurenic acid in biological samples from human patients.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Applicant: Nestec S.A.
    Inventors: Fabiyola Selvaraj, Fred Princen, Sharat Singh
  • Pathway specific markers for diagnosing irritable bowel syndrome
    Patent number: 9739786
    Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: August 22, 2017
    Assignee: NESTEC S.A.
    Inventors: Stefan Westin, Fabiyola Selvaraj, Fred Princen, Sharat Singh
  • Method for determining the risk of crohn's disease-related complications
    Patent number: 9732385
    Abstract: The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and/or progression to surgery.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: August 15, 2017
    Assignee: NESTEC S.A.
    Inventors: Derren Barken, Fred Princen, Leonard Eggleston, Sharat Singh
  • METHODS FOR PREDICTING RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER TO THERAPY
    Publication number: 20170227542
    Abstract: The present invention provides compositions and methods for detecting the expression and/or activation levels of components of signal transduction pathways in tumor cells such as triple-negative metastatic breast tumor cells. Information on the expression and/or activation levels of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Application
    Filed: September 20, 2016
    Publication date: August 10, 2017
    Applicant: DiaTech Holdings, Inc.
    Inventors: Xinjun Liu, Phillip Kim, Richard Kirkland, Tani Lee, Belen Ybarrondo, Sharat Singh
  • Biomarkers for determining sensitivity of breast cancer cells to HER2-targeted therapy
    Patent number: 9726669
    Abstract: The present invention provides compositions and methods for detecting the expression and/or activation states of components of signal transduction pathways in cells such as tumor cells. Information on the expression and/or activation states of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: August 8, 2017
    Assignee: PIERIAN HOLDINGS, INC.
    Inventors: Phillip Kim, Xinjun Liu, Richard Kirkland, Tani Lee, Belen Ybarrondo, Sharat Singh
  • METHODS FOR PREDICTING CLINICAL OUTCOMES IN SUBJECTS AFFLICTED WITH ULCERATIVE COLITIS
    Publication number: 20170219605
    Abstract: The present invention provides methods for predicting clinical outcome from a sample of a subject having ulcerative colitis (UC), comprising determining a prognostic marker profile and classifying the subject as either a responder or a non-responder. The methods can be used to monitor and to predict the progression of UC, by determining the likelihood for UC to progress either rapidly or slowly in an individual based on the presence or level of at least one marker in a sample. The methods can also be used to predict the regression of UC, by determining the likelihood for UC to regress either rapidly or slowly in an individual.
    Type: Application
    Filed: April 11, 2017
    Publication date: August 3, 2017
    Inventors: Sharat Singh, Anjali Jain
  • Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
    Patent number: 9719995
    Abstract: The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy. The present invention further provides methods for the rational selection of therapy with one or more anticancer drugs tailored to target signal transduction pathway components with dysregulated expression and/or activation levels in patients with somatic mutations in an oncogene.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 1, 2017
    Assignee: PIERIAN HOLDINGS, INC.
    Inventors: Phillip Kim, Sharat Singh
  • Assays for the Detection of Anti-TNF Drugs and Autoantibodies
    Publication number: 20170184588
    Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.
    Type: Application
    Filed: October 19, 2016
    Publication date: June 29, 2017
    Inventors: Sharat Singh, Shui-Long Wang, Linda Ohrmund
  • ANTIBODY-BASED ARRAYS FOR DETECTING MULTIPLE SIGNAL TRANSDUCERS IN RARE CIRCULATING CELLS
    Publication number: 20170184592
    Abstract: The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.
    Type: Application
    Filed: January 6, 2017
    Publication date: June 29, 2017
    Applicant: NESTEC S.A.
    Inventors: Jeanne Harvey, Sharat Singh, Phillip Kim, Xinjun Liu, Robert Barham, Limin Liu
  • ASSAYS FOR DETECTING NEUTRALIZING AUTOANTIBODIES TO BIOLOGIC THERAPY
    Publication number: 20170176433
    Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.
    Type: Application
    Filed: September 1, 2016
    Publication date: June 22, 2017
    Applicant: NESTEC S.A.
    Inventors: Scott Hauenstein, Linda Ohrmund, Sharat Singh, Shui Long Wang
  • Profiling of signal pathway proteins to determine therapeutic efficacy
    Patent number: 9664683
    Abstract: The present invention provides methods for detecting, measuring and quantitating the activation states of components of the PI3K signaling pathway in cells such as tumor cells. In particular embodiments, the present invention enable the determination of tumor adaptation to anticancer therapy. Accordingly, the present invention provides methods for improved cancer therapy selection/adjustment and disease monitoring.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: May 30, 2017
    Assignee: PIERIAN HOLDINGS, INC.
    Inventors: Sharat Singh, Phillip Kim
  • DYNAMIC CACHING SYSTEM
    Publication number: 20170052976
    Abstract: A computer implemented system and method for implementing a dynamically correcting cache is disclosed. The dynamically correcting cache is capable of correcting itself by dynamically reflecting any modifications inflicted upon the data/information to be stored in the cache memory. Further, the cache memory is refreshed at predetermined time intervals and also based on predetermined criteria, thereby ensuring a high cache hit rate. The dynamically correcting cache memory is bypassed for certain user queries prioritized based on a predetermined criteria. The dynamically correcting cache manages an inventory shared between multiple non-cooperative web-based, computer-implemented platforms. The dynamically correcting cache is directed to reducing caching errors in web based computer implemented platforms.
    Type: Application
    Filed: January 28, 2016
    Publication date: February 23, 2017
    Inventors: AKSHAT VERMA, ZAFAR ANSARI, ANIRBAN BASU, ABHILASH JAIN, PAWAN KUMAR, SUNIL KUMAR, VINEET PANDITA, DHAWAL PATEL, RAKESH RANJAN, SHUBHAM SRIVASTAVA, SHARAT SINGH
  • Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
    Patent number: 9575066
    Abstract: The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: February 21, 2017
    Assignee: NESTEC S.A.
    Inventors: Jeanne Harvey, Sharat Singh, Phillip Kim, Xinjun Liu, Robert Barham, Limin Liu